comparison between short course radiotherapy and long course radiotherapy in Rectal cancer

A Randomized prospective study comparing Neoadjuvant treatment Response in Rectal Cancer, Short Course Radiotherapy followed by Chemotherapy versus Conventional Chemo-radiation: A North East India Based Tertiary Care Hospital Experience

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013917

Enrollment

Registered

2018-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Carcinoma Rectum Health Condition 2: C20- Malignant neoplasm of rectum

Interventions

Intervention1: short Course Radiotherapy followed by chemotherapy: 25Gy/5# EBRT followed by FOLFOX4 , 4 cycles (2 weekly), total duration of therapy 8 wks Control Intervention1: Long Course Chemoradio

Eligibility

Inclusion criteria

Inclusion criteria: Age >= 18 years and ECOG performance score Written informed consent Biopsy proven rectal adenocarcinoma Metastatic lateral lymphnodes (LN+) Involved mesorectal fascia (MRF+) Locally advanced tumour fulfilling at least one of the following criteria on pelvic MRI: cT2 ,cT3,cT4a cN1, cN2 Creatinine levels indicating renal clearance >= 50 ml/min Bilirubin

Exclusion criteria

Exclusion criteria: Tumour involving lumbosacral nerve roots Tumor T4b Distant metastasis (M1) Recurrent rectal cancer FAP or HNPCC, Active Chrons disease Contraindications to MRI (e.g. pacemaker) Myocardial infarction within past 12 months or clinically significant cardiac disease Inability to give informed consent Concomitant malignancies

Design outcomes

Primary

Measure	Time frame
Pathological Complete ResponseTimepoint: 12-14 week	—

Secondary

Measure	Time frame
Radiology ResponseTimepoint: 11 week	—

Countries

India

Contacts

Public ContactShashank Bansal

Dr. Bhubaneshwar Borooah Cancer Institute

mouchumee@gmail.com9435111799

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026